Instituto Neuro Científico de Singularidad Humana.Desarrollamos Inteligencia Emocional, Habilidades Ejecutivas y Singularidad Humana a través de Certificaciones Internacionales de Coaching - ACTP -ICF, PNL Practitioner & Master - Society of NLP USA Richard Bandler, ente otros cursos. Todos nuestros programas están fundamentados en recientes avances en el campo de las Neurosciencias

• Manager of a team of 25 people with fully responsibilities of Peruvian operation. Accountable for the financial results, corporate government including compliance policy and management of the human resources of the company.• During the last 2 years we have restructured the company and we have implemented a registration plan to ensure the launch of new products in the market mainly in the Gynecological area and biosimilars.• Organizational restructure successfully implemented after the 100% purchase of Gedeon Richter.• Fulfilment of the objectives of sales and profitability in the years 2014-2015-2016.• Managed to update all permits of products marketed; including the certificate of BPA. Submission of applications of the complete Gynecological portfolio, expected to be launch during de 2015-2018 period. New product launch plan for 2015-2018 submitted and approved by Regional office. Including Biosimilars products• Reconstructed whole distribution policy achieving the presence of our products nationwide.

• Accountable for the Prescription Medicines Business Unit with annual sales of 10 million USD. Member of the Local Management Committee. Member of the Regional Taskforce for the preparation of procedures and SOPs for the area of medical Prescription and also the Regional Taskforce for the preparation of a report on synergies between Peru and Ecuador.• Main Pharmaceutical products: Angiotensin Receptor antagonists (ARAs), ARAs in combination with hydrochlorothiazide, ARA in combination with amlodipine (for the treatment of hypertension; Oral anticoagulant, direct thrombin inhibitor, in the following indications: prevention of stroke in patients with atrial fibrillation, treatment of venous thromboembolism, secondary prevention of venous thromboembolism. DPP4 Direct Inhibitor, inhibitor of SGLT2, for the treatment of Diabetes Mellitus 2. Participation in the elaboration of the marketing plans for the launch of oncology products that start in 2014. During the 1st year I was also responsible for the portfolio of Gynecological -Urological, Anti-inflammatory, respiratory, CNS.• Responsible for the development and implementation of marketing plans through marketing and sales force teams. Development plans were set up for all member of the team. • Field force restructuration with the creation of 2 more in order to intensify the focus on the main products.• + 18% sales growth (2012 vs. 2011) to increase the profitability ratio in 2 percentage points on the annual target.

• Business Unit manager for a team of 33 people, including marketing and salesforce with responsibilities for oncology and hematology products with sales of over $33 million USD. • Led 2010 sales growth of +42%, 2011 sales growth of +38%, almost doubling sales in the last 2 years from $17 to $33 million USD, despite biosimilar/intended copies threat on most important key products, including Mabthera and Herceptin • Oversaw the launch of new products (Skin Cancer franchise: B-raf inhibitor for melanonoma , Hedgehog pathway inhibitor for Basal Cell carcinoma ; HER2 franchise: Pertuzumab, TDM-1 and Herceptin SC) • Member of “HER2 testing Global Taskforce in Gastric Cancer”, which developed Global guidelines for managing Herceptin in Gastric Cancer indication• Led several new local initiatives in order to increase market access from 68% to 73% through an innovator Patient Accompanying grogram and the implementation of OncoDiagnosis program.

• Led GI Multidisciplinary Marketing team of 8 people, with product responsibilities of Avastin, Herceptin, Tarceva and Xeloda in solid cancers as Colorectal, Pancreatic, Gastric and Glioblastoma. Sales of $ 10 million USD and average annually growth of 25% • Latin American Regional Business Leader for Herceptin in Gastric Cancer indication • Local Brand leader of the most strategic product: Avastin, covering 5 current indications and potential 3 new more in the next 3 years with sales of over $ 7 million USD• Developed and maintained key relationships with a variety of international, regional, and local KOLs

• Responsible for the development and implementation of marketing plans for Therapeutic areas as: Central Nervous System (Seroquel), Critical Care/Hospitalization areas including anesthetics (Diprivan), antibiotics (meronem) and proton pump inhibitors (Nexium IV). • Meronem and Seroquel became the 1st and 3rd local products in term of sales respectively.• Member of the local team who developed the successful Business case to open a new AstraZeneca affiliate in Peru

• Marketing Head for a team of 4 people (3 product manager and 1 market research), with responsibilities for primary care products with sales of over $10 million USD. • Main products: Diovan, Lescol, Lamisil, Miacalcic, Estracomb, Estraderm, calcio Forte, Voltaren, Cataflam, Foradil. • Oversaw the launch of new products (Zelmac and Starlix)

• Product Manager for Gynecological area (Miacalcic, Estracomb, Estraderm, calcio Forte).

• Responsible for the development and implementation of marketing plans for Cardiovascular (Dynacirc y Lescol), Muscle relaxant (Sirdalud), Osteoporosis (Miacalcic), Central Nervous System (Hydergina y Parlodel), Dermatology (Lamisil), Calcium therapy (Calcio Sandoz Forte).